{"SPADE_N_15163": {"Sequence Information": {"Peptide Name": "Lantibiotic Brevicillin", "Sequence": "SDSVVSDIICTTFCSVTWCQSNCC", "Sequence Length": 24, "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Antiviral", "Anticancer", "Antifungal", "Anti-Mammalian Cell"], "Binding Target": "1. Lipid Bilayer\n2. Virus replication\n3. Virus entry", "Source": "1. Brevibacillus sp. AF8", "Gene": "", "PDB ID": "", "UniProt Entry": [], "Literature": [{"Title": "Brevicillin, a novel lanthipeptide from the genus Brevibacillus with antimicrobial, antifungal, and antiviral activity.", "Pubmed ID": "36914211", "Reference": "J Appl Microbiol. 2023;134:lxad054", "Author": "Singh SS, Sharma D, Singh C, Kumar S, Singh PK, Sharma A, Das DK, Pinnaka AK, Thakur KG, Ringe RP, Korpole S", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/36914211"}], "Mass": 2601.93, "PI": 4.05, "Net Charge": -2, "Hydrophobicity": 0.66, "Frequent Amino Acids": "CST", "Absent Amino Acids": "AEGHKLMOPRUY", "Basic Residues": 0, "Acidic Residues": 2, "Hydrophobic Residues": 11, "Polar Residues": 13, "Positive Residues": 0, "Negative Residues": 2, "SPADE ID": "SPADE_N_15163", "Similar Sequences": [{"SPADE_ID": "SPADE_UN_18728", "Similarity": 1.0, "Sequence": "SDSVVSDIICTTFCSVTWCQSNCC"}, {"SPADE_ID": "SPADE_UN_14712", "Similarity": 0.5555555555555556, "Sequence": "DWLRIIWDWVCSVVSDFK"}], "Hemolytic Activity": "Rabbit erythrocytes:50% Hemolysis=6 µg/ml,Human embryonic kidney HEK293T cells:50% Cell death=25 µg/ml,Vero E6 cells:50% Cell death=25 µg/ml", "Target Organism": "Escherichia coli MTCC 1934(MIC=1.2µg/ml),Vibrio cholerae MTCC 3905(MIC=0.8µg/ml),Pseudomonas aeruginosa MTCC 1934(MIC=1.0µg/ml),Staphylococcus aureus MTCC 1430(MIC=0.8µg/ml),Listeria monocytogenes MTCC 839(MIC=0.6µg/ml),Micrococcus luteus MTCC 106(MIC=0.2µg/ml),Bacillus subtilis MTCC 121(MIC=1.2µg/ml),Candida albicans MTCC 183(MIC=40µg/ml),Candida tropicalis MTCC 184(MIC=40µg/ml),Candida glabrata MTCC 3019(MIC=30µg/ml),Candida haemulonii MTCC 2766(MIC=45µg/ml),Candida inconspicua MTCC 1074(MIC=45µg/ml),SARS-CoV-2(IC90 REP=10µg/ml),SARS-CoV PsV(IC50 E=0.5µg/ml),Human lung carcinoma A549(50% Cell death=25µg/ml)"}}}